Many drugs are still prescribed off‐label to the pediatric population. Although off‐label drug
use not supported by high level of evidence is potentially harmful, a comprehensive …

Off-label prescribing is widespread among pediatricians, and it is unlikely that this trend will
soon be bound by a uniform legal framework. This is necessitated by the fact that there are …

Individualised medicine is continuously gaining attention in pharmaceutical research. New
concepts and manufacturing technologies are required to realise this therapeutic approach …

Background Congenital heart disease (CHD) is one of the leading causes of death. Safe
and timely medical interventions, especially in children, can prolong their survival. The drugs …

In daily paediatrics, drugs are commonly used off-label, as they are not approved for
children. Approval is lacking because the required clinical studies were limited to adults in …

Background Oseltamivir and baloxavir marboxil are the two primary oral drugs approved by
the Food and Drug Administration (FDA) for treating influenza. Limited real-world evidence …

Introduction Off‐label drug use in the paediatric population is common, and the lack of high‐
quality efficacy studies poses patients at risk for failing pharmacotherapy. Next to efficacy …

Congenital heart disease is one of the most common causes of death derived from
malformations. Historically, its treatment has depended on timely diagnosis and early …

Beta-blockers are a class of medications that act on beta-adrenergic receptors and are
categorized as cardio-selective and non-selective. They are principally used to treat …

Aims To investigate the statistical association between hypoglycaemia and β‐blocker use
and to define what patient and drug characteristics could potentially increase the risk for its …